Literature DB >> 17488690

Heart disease in thalassemia intermedia: a review of the underlying pathophysiology.

Athanasios Aessopos1, Maria Kati, Dimitrios Farmakis.   

Abstract

Heart disease is the leading cause of mortality and one of the main causes of morbidity in beta-thalassemia. The clinical spectrum of the thalassemia syndrome ranges from the severe, transfusion--dependent thalassemia major and the asymptomatic carrier state. Thalassemia intermedia represents a milder form and is usually transfusion-independent. Two main factors determine cardiac disease in this form. One is the high output state that results from chronic tissue hypoxia and from hypoxia-induced compensatory reactions. The other is the vascular involvement that leads to an increased pulmonary vascular resistance and an increased systemic vascular stiffness. Valvular abnormalities and iron overload also contribute to a less extent. As a result, both right and left ventricles have to maintain a high cardiac output level through a stiff vascular bed. Right heart involvement with age-related pulmonary hypertension followed by congestive heart failure dominates the clinical picture. Although the left heart is also affected, systolic left ventricular function is usually preserved but this may also be decompensated under conditions characterized by excessive cardiac work load.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488690     DOI: 10.3324/haematol.10915

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  29 in total

Review 1.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  Cardiomyocyte ultrastructural damage in β-thalassaemic mice.

Authors:  Chanita Sanyear; Punnee Butthep; Ramaneeya Nithipongvanich; Pornpan Sirankapracha; Pranee Winichagoon; Suthat Fucharoen; Saovaros Svasti
Journal:  Int J Exp Pathol       Date:  2013-10       Impact factor: 1.925

3.  Cardiovascular magnetic resonance and thalassaemia.

Authors:  J P Carpenter; D J Pennell
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-02       Impact factor: 2.357

Review 4.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

5.  The Interplay between Molten Globules and Heme Disassociation Defines Human Hemoglobin Disassembly.

Authors:  Premila P Samuel; Mark A White; William C Ou; David A Case; George N Phillips; John S Olson
Journal:  Biophys J       Date:  2020-02-04       Impact factor: 4.033

6.  Hemodynamic characteristics and predictors of pulmonary hypertension in patients with sickle cell disease.

Authors:  Melissa C Caughey; Alan L Hinderliter; Susan K Jones; Sanjeev P Shah; Kenneth I Ataga
Journal:  Am J Cardiol       Date:  2012-02-15       Impact factor: 2.778

7.  Depleted nitric oxide and prostaglandin E2 levels are correlated with endothelial dysfunction in β-thalassemia/HbE patients.

Authors:  Sudarat Satitthummanid; Noppacharn Uaprasert; Smonporn Boonyaratavej Songmuang; Ponlapat Rojnuckarin; Piyaratana Tosukhowong; Pranee Sutcharitchan; Suphot Srimahachota
Journal:  Int J Hematol       Date:  2017-05-04       Impact factor: 2.490

8.  Impact of β-thalassemia trait carrier state on cardiovascular risk factors and metabolic profile in patients with newly diagnosed hypertension.

Authors:  A I Triantafyllou; G P Vyssoulis; E A Karpanou; P L Karkalousos; E A Triantafyllou; A Aessopos; D T Farmakis
Journal:  J Hum Hypertens       Date:  2013-10-24       Impact factor: 3.012

9.  Inadequate dietary intake in patients with thalassemia.

Authors:  Ellen B Fung; Yan Xu; Felicia Trachtenberg; Isaac Odame; Janet L Kwiatkowski; Ellis J Neufeld; Alexis A Thompson; Jeanne Boudreaux; Charles T Quinn; Elliott P Vichinsky
Journal:  J Acad Nutr Diet       Date:  2012-05-01       Impact factor: 4.910

10.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia.

Authors:  Khaled M Musallam; Maria Domenica Cappellini; John C Wood; Irene Motta; Giovanna Graziadei; Hani Tamim; Ali T Taher
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.